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Introduction
In 2008, 18,774 cases of non-small-cell lung cancer (NSCLC) were
diagnosed in Korea, representing 10.5% of all cancer incidence [1]. Thirty-
four percent of those diagnosed with NSCLC were 70 years or older in
age. Although mortality from NSCLC has decreased in patients aged 60
years and younger, it has increased in those aged above 70 years. In the
past, the elderly have often been excluded from clinical trials because of
age-related decrease in organ function, such as reductions in renal and he-
patic function, which potentially increase the risk of chemotherapy-in-
duced toxicity. Unfortunately, elderly patients have been empirically un-
dertreated even if they had a good performance status because of the
widespread preconception that cancer in older patients is less aggressive
and that older patients are inherently intolerant to chemotherapy. In addi-
tion, elderly patients have severe cardiopulmonary comorbidity [2,3].
Elderly patients show a number of age-related health issues that can
affect their tolerance to cancer treatments. Problems with maintaining
fluid homeostasis may develop because of decreased cardiovascular re-
serve following increased arterial stiffening and systolic blood pressure
Cancer Res Treat. 2011;43(4):217-224
pISSN 1598-2998, eISSN 2005-9256
http://dx.doi.org/10.4143/crt.2011.43.4.217
Sang Hoon Chun,MD1
Ji Eun Lee, MD1
Mi Hee Park, MD1
Jin-Hyoung Kang, MD1
Young Kyoon Kim, MD2
Young-Pil Wang, MD3
Jae Kil Park, MD3
Hoon-Kyo Kim, MD1
Divisions of 1Oncology and 2Pulmonology,
Department of Internal Medicine, 
3Department of Chest Surgery, 
The Catholic University of Korea School of
Medicine, Seoul, Korea
Correspondence: Jin-Hyoung Kang, MD
Division of Oncology, Department of 
Internal Medicine, The Catholic University of
Korea School of Medicine, 505 Banpo-dong, 
Seocho-gu, Seoul 137-701, Korea
Tel: 82-2-2258-6043
Fax: 82-2-594-6043
E-mail: jinkang@catholic.ac.kr
Received  May 5, 2011
Accepted  June 27, 2011
Purpose
This study aimed to analyze the efficacy and toxicity of gemcitabine plus platinum chemotherapy
for patients aged 70 years or older with advanced non-small-cell lung cancer (NSCLC). 
Materials and Methods
We reviewed the records of stage IIIB, IV NSCLC patients or surgically inoperable stage II, IIIA
NSCLC patients who were aged 70 years or older when treated with gemcitabine (1,250 mg/m2)
plus cisplatin (75 mg/m2) or carboplatin (AUC5) chemotherapy from 2001 to 2010 at Seoul St. Mary’s
Hospital, Uijeongbu St. Mary’s Hospital and St. Vincent’s Hospital. Gemcitabine was administered
on days 1 and 8, and cisplatin or carboplatin was administered on day 1. Treatments were repeated
every 3 weeks for a maximum of 4 cycles.
Results
The median age of the 62 patients was 73.5 years (range, 70 to 84 years). Forty-one (66%) patients
exhibited comorbidity. The mean number of treatment cycles was 3.9. The compared average
relative dose intensity of gemcitabine plus platinum chemotherapy was 84.8%. The median pro-
gression-free survival and overall survival (OS) were 5.0 months and 9.4 months, respectively. Re-
duced Eastern Cooperative Oncology Group (ECOG) performance status (none vs. ≥1) and weight
loss (＜5% vs. ≥5%) after treatment were found to have a significant effect on OS (p=0.01). 
Conclusion
Gemcitabine plus platinum chemotherapy is an effective treatment option with an acceptable
level of toxicity in patients aged 70 years or older with good performance status in advanced
NSCLC.
Key words
Non-small-cell lung carcinoma, Aged, Gemcitabine, 
Platinum, Drug therapy
Original Article Open Access
Gemcitabine Plus Platinum Combination Chemotherapy for
Elderly Patients with Advanced Non-small Cell Lung Cancer: 
A Retrospective Analysis
│http://www.cancerresearchandtreatment.org│
│http://www.e-crt.org│
Copyright ⓒ2011 by  the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0/)whichpermitsunrestrictednon-commercialuse,distribution, andreproductioninanymedium,providedtheoriginalworkisproperlycited.
217Cancer Res Treat. 2011;43(4):217-224
218 CANCER  RESEARCH AND  TREATMENT
and decreased maximal heart rate. Moreover, decreased diffusion capacity,
vital capacity, and one-second forced expiratory volume may result in de-
creased pulmonary function. Elderly patients are more sensitive to neu-
rologic complications after cancer treatment because of decreased brain
mass and cerebral blood flow. The elderly are also more likely to suffer
from prolonged gastrointestinal toxicity owing to diminished turnover of
gastrointestinal mucosa. In addition, renal and hepatic blood flow de-
creases with aging; this may affect the clearance of chemotherapeutic
agents [4,5].
The development of medicine and improvement in nutritional status
resulted in the increased performance status of elderly patients over the
last decade in Korea. It may be difficult to determine benefits and tolerance
to chemotherapy based on age alone. However, elderly patients who are
physiologically younger than their peers are good candidates for platinum-
based combination chemotherapy. Therefore, we analyzed the efficacy
and toxicity of platinum plus gemcitabine chemotherapy in advanced
NSCLC patients aged 70 years or older.
M ater ials  and  Methods
1. Inclusion criteria for patients
We retrospectively reviewed the records of patients aged 70 years or
older, who were enrolled in this study if they had been histologically or
cytologically diagnosed with stage IIIB, IV NSCLC or had recurrent or
surgically inoperable stage II, IIIA NSCLC. A total of 543 patients were
diagnosed as NSCLC and 207 patients received anti-cancer treatment be-
tween 2001 and 2010 at Seoul St. Mary’s Hospital, Uijeongbu St. Mary’s
Hospital and St. Vincent’s Hospital in Korea. To be eligible, patients had
to have 1) measurable lesions; 2) an Eastern Cooperative Oncology Group
(ECOG) performance status of 0, 1, or 2; and 3) adequate organ function.
We excluded patients with clinically overt brain metastases and those who
had previously received chemotherapy into five years. Patients who had
undergone radiotherapy were eligible if the radiation treatment was com-
pleted at least 2 weeks before enrollment. Cancer staging was performed
according to the 7th edition of the American Joint Committee on Cancer.
2. Treatment schedule
Gemcitabine was administered at a dose of 1,250 mg/m2on days 1 and
8. Cisplatin was administered at a dose of 75 mg/m2on day 1. Carboplatin
was administered at a dose of AUC5 on day 1. The carboplatin dose was
calculated using the Chatelut formula [6]. Selection of cisplatin or carbo-
platin administration during the first cycle was determined by the physi-
cian. If cisplatin induced grade 3 or higher for nephrotoxicity, ototoxicity,
or neurotoxicity, it was replaced with carboplatin. The administration of
both drugs was reduced or omitted in the case of hematologic toxicity ac-
cording to the dosage adjustment criteria: 80% of the full doses of gem-
citabine and cisplatin/carboplatin were given if the absolute granulocyte
count was between 500/mm3and 100/mm3and/or the platelet count was
between 50,000/mm3and 75,000/mm3. Chemotherapy was delayed by 1
week if the absolute granulocyte count was below 500/mm3 and/or the
platelet count was below 50,000/mm3. Next chemotherapy was omitted
if it was delayed by 2 weeks. This regimen was repeated every 3 weeks
for a minimum of 4 cycles per patient unless disease progression was de-
tected or there were unacceptable toxicities. Second-line treatment was
determined by the physician.
3. Evaluation of tumor response and toxicity
Before each treatment cycle, patient history was obtained and physical
examination, complete blood cell count, and blood chemistry were per-
formed. Objective responses were evaluated by computerized tomogra-
phy every 2 treatment cycles. The response evaluation was performed
according to Response Evaluation Criteria in Solid Tumors (ver. 1.1). The
best response for each patient was used for analysis. The objective re-
sponse rate (ORR) represents the percentage of patients that had a partial
response (PR) or a complete response (CR). The disease control rate
(DCR) was defined as the percentage of patients that had a PR, CR, or
stable disease. Occurrence of cancer-related death before response eval-
uation was defined as progressive disease. Toxicity was assessed by the
National Cancer Institute Common Toxicity Criteria (ver. 3.0). For toxicity
analysis, the worst data for each patient in all cycles of treatment were
used.
4. Statistical analysis
The delivered dose intensity was the total dose delivered over the entire
period of chemotherapy. The relative dose intensity (RDI) was the ratio
of delivered dose intensity to the reference standard dose and was ex-
pressed in percentage. Overall survival was defined as the time between
the date of treatment initiation and the last date that the patient was known
to be dead or alive. Progression-free survival (PFS) was defined as the
time from the date of treatment initiation to disease progression or to death
from disease progression.
Fisher’s exact test and Student’s t-test were used to compare patient
characteristics. Fisher’s exact test was used to compare response rates,
whereas Student’s t-test was used to compare average dose intensities and
levels of toxicity. Survival estimates and comparisons were calculated by
the Kaplan-Meier method and the log-rank test, respectively. A univariate
Cox proportional hazards model was used to summarize the association
between clinical and pathological characteristics. Variables that showed
weak evidence of association with the outcome (p＜0.20) were considered
for inclusion into a multivariable Cox proportional hazards model. p-value
of less than 0.05 was considered statistically significant. Statistical analysis
was performed using SPSS ver. 18.0 (SPSS Inc., Chicago, IL).Sang Hoon Chun, Gemcitabine Combined with Platinum for NSCLC
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R esults
1. Patient characteristics
The record of 62 patients with NSCLC was reviewed retrospectively.
The study sample consisted of 42 men (67.7%) and 20 women (32.3%)
aged 70 to 84 years (mean, 73.5 years). The tumor histology was adeno-
carcinoma in 33 patients, squamous cell carcinoma in 20, large cell car-
cinoma in 2, poorly differentiated carcinoma in 3, pleomorphic carcinoma
Values are presented as number (%). ECOG, Eastern Cooperative Oncology Group; HBP, hypertension; CAD, coronary artery disease; COPD,
chronic obstructive pulmonary disease; DM, diabetes mellitus; LDH, lactate dehydrogenase.
Table 1. Baseline characteristics of patients with non-small cell lung cancer
Overall patients
Age (yr)
p-value
70-74 ≥75
Gender     0.48
Male 42 (67.7) 31 (50.0) 11 (17.7)
Female 20 (32.3) 13 (21.0) 7 (11.3)
Median age (range, yr) 73.5 (70-84) 71.9ﾱ1.5 77.4ﾱ2.1 0.55
No. (%) 44 (71.0) 18 (29.0)
ECOG performance status 0.80
0 1 (1.7) 1 (1.6) 0 (0)
1 50 (80.6) 35 (56.5) 15 (24.2)
2 11 (17.7) 8 (12.9) 3 (4.8)
Smoking status (pack/yr) 35ﾱ20 41ﾱ20 0.83
Never-smoker 24 (38.8) 19 (30.7) 5 (8.1) 0.02
Ex-smoker 19 (30.6) 9 (14.5) 10 (16.1)
Current-smoker 19 (30.6)  16 (25.8) 3 (4.8)
Histology 0.11
Adenocarcinoma 33 (53.2) 19 (30.6) 14 (22.6)
Squamous cell carcinoma 20 (32.3) 17 (27.4) 3 (4.9)
Large cell carcinoma 2 (3.2) 2 (3.2) 0 (0)
Other 7 (11.3) 6 (9.7) 1 (1.6)
Stage 0.32
IIB 1 (1.6) 1 (1.6) 0 (0)
IIIA 2 (3.2) 1 (1.6) 1 (1.6)
IIIB 15 (24.2) 13 (21.0) 2 (3.2)
IV 44 (71.0) 29 (46.8) 15 (24.2)
Organs involved by cancer 0.13
0 22 (35.5) 19 (30.7) 3 (4.8)
1 32 (51.6) 19 (30.6) 13 (21.0)
2 6 (9.7) 4 (6.5) 2 (3.2)
3 2 (3.2) 2 (3.2) 0 (0)
Comorbidity 0.51
None 21 (33.9) 17 (27.4) 4 (6.5)
Cardiovascular (e.g., HBP, CAD) 17 (27.5) 12 (19.4) 5 (8.1)
Respiratory (e.g., COPD) 1 (1.6) 1 (1.6) 0 (0)
Endocrine (e.g., DM, hypothyroidism) 8 (12.9) 6 (9.7) 2 (3.2)
Cardiovascular+Endocrine 6 (9.6) 3 (4.8) 3 (4.8)
Cardiovascular+Respiratory 1 (1.6) 0 (0.0) 1 (1.6)
Others (ex. previous malignancy) 8 (12.9) 5 (8.1) 3 (4.8)
Laboratory finding
Hb 12.04ﾱ1.59 11.84ﾱ1.60 12.51ﾱ1.50 0.13
LDH 461.0ﾱ226.5 465.0ﾱ165.0 451.2ﾱ341.1 0.88
Albumin 3.55ﾱ0.48 3.48ﾱ0.38 3.72ﾱ0.63 0.06Cancer Res Treat. 2011;43(4):217-224
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in 3, and mucoepidermoid carcinoma in 1 patient. Three patients (4.8%)
with stage IIB and IIIA were eligible for the study because they were in-
operable. The most frequent comorbidity was cardiovascular disease (hy-
pertension, coronary artery disease, or congestive heart failure), which
was reported in 38.7% of patients. The second most common comorbidity
was endocrine disease (diabetes mellitus or hypothyroidism). Seven pa-
tients had previously received anti-cancer treatment due to ovarian cancer,
prostate cancer, hepatocellular carcinoma, head and neck cancer, stomach
cancer, and bladder cancer; 2 ovarian cancer patients received surgery fol-
lowed by adjuvant chemotherapy. Hepatocellualr carcinoma, glottis can-
cer, prostate cancer, bladder cancer, stomach cancer patients received
surgery alone. All 7 patients were in complete remission after more than
5 years of the NSCLC being diagnosed. These data are summarized in
Table 1.
2. Treatment and average RDI
Three patients aged 70 to 74 years (7%) discontinued treatment because
of disease progression. Fifteen patients (24%) discontinued treatment due
to toxicity and a decrease in performance status. Eleven of these patients
were 70 to 74 year in age, whereas 4 were 75 years and older. The mean
duration of treatment for patients who were 70 to 74 years of age and 75
years or older was 3.8 months and 2.5 months, respectively. Nine patients
Table 2. Average relative dose intensity (RDI) of gemcitabine/platinum chemotherapy
Overall patients
Age (yr)
p-value
70-74 ≥75
Mean no. of treatment cycle 3.94ﾱ1.69 4.02ﾱ1.79 3.72ﾱ1.45 0.53
Average RDI of gemcitabine+platinum (%) 84.84ﾱ21.00 87.41ﾱ17.46 75.72ﾱ29.91 0.12
Average RDI of gemcitabine (%) 82.76ﾱ22.23 85.48ﾱ18.50 75.72ﾱ28.91 0.20
Average RDI of platinum (%) 86.92ﾱ21.20 88.73ﾱ18.52 82.50ﾱ26.74 0.30
Table 3. Tumor responses to gemcitabine/platinum chemotherapy
Overall patients
Age (yr)
70-74 ≥75
Complete remission 1 (1.6) 1 (1.6) 0 (0)
Partial remission 19 (30.6) 16 (25.8) 3 (4.8)
Stable disease 35 (56.5) 21 (33.9) 14 (22.6)
Progressive disease 7 (11.3) 6 (9.7) 1 (1.6)
Total 62 (100) 44 (71) 18 (29)
Values are presented as number (%).
Table 4. Hazard ratios for progression-free survival (n=62)
Covariates Hazard ratio (95% CI) p-value
Univariate analysis
Gender (male vs. female) 1.35 (0.75-2.42) 0.31
Smoking (non-smoker vs. current-smoker) 0.70 (0.33-1.52) 0.37
Stage (IV vs. others) 1.33 (0.25-6.94) 0.74
ECOG change (none vs. decreased more than 1 grade) 0.96 (0.53-1.73) 0.89
Weight loss (＜5% vs. ≥5%) 0.61 (0.31-1.19) 0.15
GFR loss (＜16% vs. ≥16%) 0.46 (0.24-0.89) 0.02
Gemcitabine average RDI (＜85% vs. ≥85%) 0.77 (0.43-1.42) 0.41
Platinum average RDI (＜80% vs. ≥80%) 0.60 (0.29-1.24) 0.17
Multivariate analysis
Weight loss (＜5% vs. ≥5%) 0.49 (0.20-1.16) 0.11   
GFR loss (＜16% vs. ≥16%) 0.37 (0.17-0.80) 0.01
Platinum average RDI (＜80% vs. ≥80%) 0.90 (0.37-2.18) 0.90
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; GFR, glomerular filtration rate; RDI, relative dose intensity.Sang Hoon Chun, Gemcitabine Combined with Platinum for NSCLC
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(6 belonged to the 70 to 74 year old group and 3 to the group 75 years or
older group) initially treated gemcitabine-carboplatin chemotherapy. For
5 patients (70 to 74 years of age), cisplatin was replaced with carboplatin
because of ototoxicity (3 patients), nephrotoxicity (1 patient), and neuro-
toxicity (1 patient). The average RDI of all patients was 84.8ﾱ21.0%. The
average RDI between patients aged 70 to 74 years and those older than
75 years was not significantly different (p=0.12). These data are summa-
rized in Table 2.
3. Clinical response rate
The ORR and DCR were not significantly different (p=0.20 and
p=0.66, respectively) between the two patient groups: those of the 70 to
74 year old patients were 38.6% and 86.4%, and those of the patients aged
75 years or older were 16.7% and 94.4%, respectively. The response eval-
uations are summarized in Table 3.
4. Analysis of recurrence and survival
The median overall survival (OS) and PFS were 9.4 months (95% con-
fidence interval [CI], 6.72 to 13.14 months) and 5.0 months (95% CI, 3.64
to 6.42 months), respectively. Analysis of the curve for OS (8.1 months
vs. 17.7 months, p=0.18; Fig. 1) and PFS (5.9 months vs. 4.9 months,
p=0.44; Fig. 2) revealed that there was no significant difference between
patients aged 70 to 74 years and those older than 75 years. The overall 1-
year survival rate was 42%. When patients were separated into younger
and older age groups, the 1-year survival rate was 35% and 55%, respec-
tively.
Post-therapeutic  weight  loss  (＜5%  vs.  ≥5%),  post-therapeutic
glomerular filtration rate (GFR) loss (＜16% vs. ≥16%), and average
RDI of platinum (＜80% vs. ≥80%) were all associated with PFS, as
determined by univariate analysis. After adjustment of the variables, mul-
tivariable analysis revealed that GFR loss (hazard ratio [HR], 0.37; 95%
CI, 0.17 to 0.80; p=0.01) remained as a significant factor affecting PFS.
The performance status change (none vs. ＞1), post-therapeutic weight
loss (＜5% vs. ≥5%), post-therapeutic GFR loss (＜16% vs. ≥16%),
average RDI of gemcitabine (＜85% vs. ≥85%), and average RDI of
platinum (＜80% vs. ≥80%) were all associated with OS, as determined
by univariate analysis. After adjustment of the variables above, multivari-
able analysis revealed that the performance status change (HR, 2.65; 95%
CI, 1.27 to 5.54; p=0.01) and weight loss (HR, 0.26; 95% CI, 0.09 to 0.79;
p=0.01) remained as significant factors affecting OS (Tables 4 and 5).
5. Toxicity
Grade 3 to 4 febrile neutropenia was reported for 6 patients in 70 to 74
year old group and for 1 patient from the group aged 75 years and older.
Hospitalization due to febrile neutropenia was not significantly different
between the younger group (9.0ﾱ3.6 days) and the older group (6.0ﾱ4.2
days) (p=0.50). 
Death during treatment period was reported for 3 patients only in 70 to
74 year old group. One patient died as a result of catheter-related sepsis
after 1 cycle of chemotherapy and another patient expired because of acute
Fig. 1. (A) Overall survival of all patients in this study. (B) Overall survival for 70-74 year-olds compared with older than 75 year-olds.Cancer Res Treat. 2011;43(4):217-224
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respiratory distress syndrome induced by aspiration pneumonia after 6
cycles of treatment. Another patient expired due to acute kidney injury
after 1 cycle of treatment. Three patients refused further treatment after 4
cycles of treatment after experiencing grade 3 vomiting and general weak-
ness.
There was no significant difference between the groups in hematologic
or non-hematologic toxicity, or in the usage of granulocyte colony-stim-
ulating factor and transfusion of packed red cell and platelets. Pre- and
post-therapeutic weight change was calculated and a significant difference
was observed (p=0.047). After treatment, 37 patients (29 belong to the 70
to 74 year old group, 8 patients to the group 75 years or older) showed
decrease in weight of more than 5%.
The difference in the pre- and post-therapeutic GFR values was calcu-
lated. The GFR of 38 patients (25 patients belong to the 70 to 74 year old
group and 13 patients to the 75 years or older group) decreased by more
than 16% after treatment which is a decrease of 1 grade or more according
Table 5. Hazard ratios for overall survival progression-free survival (n=62)
Covariates Hazard ratio (95% CI) p-value
Univariate analysis
Gender (male vs. female) 1.13 (0.63-2.01) 0.69
Smoking (non-smoker vs. current-smoker) 0.70 (0.33-1.52) 0.37
Stage (IV vs. others) 2.63 (0.52-13.17) 0.24
ECOG change (none vs. decreased more than 1 grade) 3.51 (1.92-6.41) 0.001
Weight loss (＜5% vs. ≥5%) 0.35 (0.18-0.66) 0.001
GFR loss (＜16% vs. ≥16%) 0.56 (0.29-1.07) 0.08
Gemcitabine average RDI (＜85% vs. ≥85%) 0.41 (0.22-0.76) 0.005
Platinum average RDI (＜80% vs. ≥80%) 0.36 (0.18-0.74) 0.005
Multivariate analysis
ECOG change (none vs. decreased more than 1 grade) 2.65 (1.27-5.54) 0.01
Weight loss (＜5% vs. ≥5%) 0.26 (0.09-0.79) 0.01  
GFR loss (＜16% vs. ≥16%) 0.78 (0.32-1.89) 0.58
Gemcitabine average RDI (＜85% vs. ≥85%) 0.92 (0.32-2.67) 0.88
Platinum average RDI (＜80% vs. ≥80%) 0.67 (0.21-2.21) 0.51
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; GFR, glomerular filtration rate; RDI, relative dose intensity.
Fig. 2.  (A) Progression-free survival of all patients in this study. (B) Progression-free survival for 70-74 year-olds compared with older than 75
year-olds.Sang Hoon Chun, Gemcitabine Combined with Platinum for NSCLC
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to the definition of chronic kidney disease, but this change was not sig-
nificantly different (p=0.51). Table 6 shows the toxicity profile.
6. Second-line treatment
Ten patients were lost to follow up after the first-line treatment. Thirty-
one patients failed in response to primary treatment or experienced disease
progression after first-line chemotherapy. Fifteen patients (24.2%) were
treated by epidermal growth factor receptor tyrosine kinase inhibitor, 10
(16.1%) by docetaxel, 4 (6.5%) by pemetrexed, 1 (1.6%) by paclitaxel-
carboplatin chemotherapy and 1 (1.6%) by clinical trial of the novel target
agent ticilimumab.
Discussion
We evaluated the efficacy and toxicity of gemcitabine and platinum
chemotherapy for patients aged 70 years or older with advanced NSCLC.
In our study, 66.1% of patients had underlying comorbidity including car-
diovascular disease, endocrine disorders and their combination. The av-
erage RDI and mean number of treatment cycle for gemcitabine and
platinum chemotherapy were 84.8% and 3.94 cycles, respectively. The
ORR, 1-year survival rate and median OS were 32.2%, 42%, and 9.4
months, respectively. These results were similar to those of meta-analysis
for gemcitabine-containing combination chemotherapy in advanced
NSCLC showing ORR of 30%, 1-year survival rate of 37%, and median
OS of 8.7 months [7,8]. Also, a phase II clinical trial using modified sched-
ules and attenuated doses of cisplatin reported ORR of 35%, 1-year sur-
vival rate of 35%, and median OS of 11 months [9,10]. However, the
response rate of patients who were 70-74 years in age was 21.9% higher
than that of patients aged 75 years or older (38.6% vs. 16.7%). This dif-
ference between the two groups may be due to a reduction in average RDI
in the patients aged 75 years or older. 
In the multivariate analysis, GFR loss remained a significant prognostic
factor affecting PFS. Post-therapeutic performance status change and
weight loss were significant prognostic factors affecting OS. Platinum-
related severe nausea/vomiting and anorexia were more frequently ob-
served in patients with a significant change in performance status. 
In our study, grade 3 to 4 neutropenia and thrombocytopenia were ob-
served at a frequency of 54.8% and 40.3%, respectively. This incidence
was much higher than the meta-analysis of gemcitabine-containing
chemotherapy for advanced NSCLC, which reported 25% of grade 3 to
4 neutropenia and 18% of thrombocytopenia [8]. This suggests that active
supportive care and careful monitoring should be given to elderly NSCLC
patients because decreased GFR and weight loss were significant factors
affecting PFS and OS. These patients were also more vulnerable to
chemotherapy-induced myelotoxicity than younger patients.
Although recent research have revealed that the pharmacokinetics of
cisplatin does not differ depending on age [11], clinical data showed that
elderly patients experienced more profound myelotoxicity than younger
patients [12,13]. These studies suggested that a reduction in RDI arising
from GFR loss induced by cisplatin resulted in shortening of PFS.
A phase III multicenter clinical trial for advanced NSCLC in elderly
patients reported that single-agent vinorelbine improved the quality of life
and survival relative to supportive care alone [14]. However, other clinical
Table 6. Toxicity profile of gemcitabine/platinum chemotherapy
Age (yr)
70-74 ≥75
Overall patients By CTC toxicity grade By CTC toxicity grade p-value
3-4 3-4
Leukopenia 18 (29.0) 14 (22.6) 4 (6.4) 0.80
Neutropenia 34 (54.8) 24 (38.7) 10 (16.1) 0.94
Anemia 16 (25.8) 11 (17.7) 5 (8.1) 0.80
Thrombocytopenia 25 (40.3) 19 (30.6) 6 (9.7) 0.81
Febrile neutropenia  7 (11.3) 6 (9.7) 1 (1.6) 0.66
Nausea 4 (6.4) 2 (3.2) 2 (3.2) 0.19
Vomiting 3 (4.8) 2 (3.2) 1 (1.6) 0.45
Anorexia 6 (9.6) 4 (6.4) 2 (3.2) 0.55
Diarrhea 1 (1.6) 1 (1.6) 0 (0) 0.51
Mucositis 0 (0) 0 (0) 0 (0) 0.26
General weakness 11 (17.7) 7 (11.3) 4 (6.4) 0.86
Infection 4 (6.4) 2 (3.2) 2 (3.2) 0.25
Nephrotoxicity 1 (1.6) 1 (1.6) 0 (0) 0.83
Ototoxicity 0 (0) 0 (0) 0 (0) 0.31
Neurotoxicity 3 (4.8) 3 (4.8) 0 (0) 0.49
Values are presented as number (%).Cancer Res Treat. 2011;43(4):217-224
224 CANCER  RESEARCH AND  TREATMENT
studies demonstrated that the combination of vinorelbine with gemcitabine
did not improve survival rate or quality of life compared to an individual
agent [15,16]. Based on the results from these large-scale randomized
comparative clinical studies, single-agent chemotherapy has been favored
as systemic treatment for elderly NSCLC patients.
Recently, the Surveillance Epidemiology and End Results (SEER)
database at the National Cancer Institute in US evaluated the use of various
chemotherapies in adults aged older than 65 years with advanced NSCLC.
Only 25.8% of patients who received first-line chemotherapy showed an
increased adjusted 1-year survival rate as compared to those that received
no chemotherapy (27.0% vs. 11.1%). On the contrary, the use of plat-
inum-based combination chemotherapies resulted in an increased 1-year
survival rate relative to single-agent chemotherapies (30.1% vs. 19.4%)
[17]. The results of an interesting phase III clinical trial (IFCT-0501) were
presented at the 2010 annual meeting of American Society of Clinical
Oncology (ASCO). A total of 451 adults aged 70 to 89 years were ran-
domized for treatment with single-agent chemotherapy (gemcitabine or
vinorelbine) or combination chemotherapy (monthly carboplatin plus
weekly paclitaxel). Three hundred and thirteen patients were analyzed for
anti-tumor efficacy and toxicity of different treatment arms. The OS and
the PFS were significantly longer in the combination arm. Although
hematologic toxicities were more common in the combination arm, there
was no significant difference in early deaths [18].
Based on our result and recent reports, we recommend that the dose of
platinum plus gemcitabine chemotherapy be reduced by 15% at the be-
ginning time of treatment for advanced NSCLC patients who are older
than 70 years. In addition, prospective clinical trials are required to deter-
mine the appropriate doses and scheduling of platinum-based chemother-
apy in healthy elderly patients with NSCLC.
C onclusion
Oncologists ought to focus on careful monitoring of chemotherapy-in-
duced toxicity, especially for elderly patients. Moreover, strong supportive
care should be given to elderly NSCLC patients because weight loss and
decreased GFR ultimately leads to poor clinical outcome. Gemcitabine
plus platinum combination chemotherapy for elderly NSCLC patients
with good performance status seems to be one of the effective treatment
options with an acceptable level of toxicity on the assumption that ade-
quate dose reduction and careful monitoring in advance are constituted.
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